22. Orilissa

AbbVie
(AbbVie)

Active ingredient: elagolix 
Disease: endometriosis 
Peak sales estimate: $2 billion 
Approved: July 24 
Company: AbbVie and Neurocrine Biosciences

The scoop: AbbVie is preparing for a future after biosimilars bite into top-seller Humira, and Orilissa is a big part of it. Execs are expecting a hefty contribution from the therapy, which this summer became the first oral drug to snag an FDA green light for endometriosis in more than a decade. Approval for two dosage strengths will help toward that goal, as will a lack of black-box safety warnings or monitoring requirements for bone mineral density changes, Goldman Sachs analyst Jami Rubin wrote at the time. AbbVie isn’t stopping with endometriosis, though. In November, Orilissa topped placebo in a pair of phase 3 trials at reducing heavy menstrual bleeding related to uterine fibroids, and AbbVie, along with partner Neurocrine Biosciences, expects to file for FDA approval in the middle of 2019. — Carly Helfand 

22. Orilissa
Read more on

Suggested Articles

Dr. Ian Hudson is stepping down after six years in charge of the Medicines and Healthcare products Regulatory Agency next month.

Finch thinks it has a shot at winning FDA approval of the full-spectrum microbiota drug if the ongoing clinical study generates “compelling results.”

Chinook Therapeutics raised $65 million to do for kidney disease what precision medicine has done for cancer. It aims to be in the clinic by 2021.